Before our study, Bai et al also reported PD-L1 status did not significantly associate with PFS and OS of EGFR-TKI treatment in a meta-analysis.[34] Interestingly, studies from Azuma et al and Akbay et al suggested inhibiting EGFR signaling with erlotinib could downregulate the expression of PD-L1 in EGFR-mutant NSCLC cell lines.[35,36] Basing on the results of preclinical studies, EGFR-TKIs are supposed to inhibit tumor not only by the directly blocking EGFR signaling, but also by consequently restoring antitumor immune response such as PD-L1 downregulation. Here, EGFR is linked to non-small cell lung carcinoma.